Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 620 Memorial Dr w 100, Cambridge, MA 02139, USA
- Website
- emmune.bio
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Emmune Inc., a for-profit biotech company headquartered in Cambridge, Massachusetts, is a recipient of federal Small Business Innovation Research (SBIR) grants from the National Institutes of Health, focused on non-viral gene therapy development and recombinant protein therapeutics for HIV and cardiovascular disease. The company operates exclusively as a prime recipient on the federal grant side (100% of awards) with no federal contract prime work or federal contract subcontract work in the source data.
Emmune's federal grant portfolio concentrates entirely within HHS/NIH, with ten of thirteen awards funded by the National Institute of Allergy and Infectious Diseases (NIAID), one by the National Heart, Lung, and Blood Institute (NHLBI), one by the National Center for Advancing Translational Sciences (NCATS), and one by NIH broadly. Recent representative work includes a fast-track SBIR grant from NHLBI awarded September 1, 2026 ($299,664) for non-viral lipid nanoparticle (LNP)-based gene therapy vectors targeting atherosclerotic cardiovascular disease, with Phase I proof-of-concept in mice and Phase II optimization and non-human primate validation through February 28, 2027. Emmune received two August 2026 NIAID fast-track SBIR grants totaling roughly $299,000 for pre-clinical IND-enabling studies of ECD4-IG, a long-acting recombinant antibody-like therapeutic for HIV combining parts of HIV's CD4 receptor and CCR5 coreceptor fused to an antibody Fc domain, with pharmacokinetic, tolerability, and GLP toxicology work in macaques completing January 31, 2027. Earlier NIAID funding supported basic science development of non-viral gene therapy with ECD4-IG (June 2025), IND-enabling studies and in vitro assays (May 2025), manufacturing process development (January 2023 through August 2028), and SARS-CoV-2 vaccine development using engineered glycosylation sites in receptor binding domains (August 2022 through July 2026).
Combined obligated federal dollars across all thirteen awards total $35.1 million. Three awards reach ultimate completion inside the next twenty-four months, creating near-term recompete opportunity. Activity has been episodic — two awards in 2021, one each in 2022 and 2023, then two in 2025 and two in 2026 — rather than sustained linear growth. Emmune's core capability set centers on non-viral gene delivery engineering using lipid nanoparticles, recombinant protein manufacture and formulation development, and translational immunology work, with all recent work tracking toward clinical-stage HIV therapeutics and cardiovascular gene therapy products rather than defense or civilian agency support missions.
Quick answers
Is Emmune Inc. registered in SAM.gov?
Yes. Emmune Inc.'s SAM.gov registration is active through May 11, 2027.
What is Emmune Inc.'s CAGE code?
Emmune Inc.'s CAGE code is 7A4Z5, and its Unique Entity ID (UEI) is N65ZDYUGWAH8.
What is Emmune Inc.'s most recent federal award?
Emmune Inc.'s most recent federal grant award is Non-viral gene therapy to treat and prevent atherosclerosis (R44HL184837), from National Heart Lung and Blood Institute (NIH), on September 1, 2026.
On GovTribe
See Emmune Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors